| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/20/2000 | WO2000003036A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 01/20/2000 | WO2000003016A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 01/20/2000 | WO2000003015A2 Human transport protein homologs |
| 01/20/2000 | WO2000002923A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 01/20/2000 | WO2000002917A2 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | WO2000002912A2 Disintegrin homologs |
| 01/20/2000 | WO2000002906A1 Dolastatin 15 derivatives |
| 01/20/2000 | WO2000002904A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |
| 01/20/2000 | WO2000002902A1 Novel inhibitors of angiogenesis and tumor growth |
| 01/20/2000 | WO2000002897A2 Delta cleavage products and methods based thereon |
| 01/20/2000 | WO2000002881A2 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein |
| 01/20/2000 | WO2000002877A2 New pharmaceutically active compounds |
| 01/20/2000 | WO2000002871A1 Novel angiogenesis inhibitors |
| 01/20/2000 | WO2000002870A1 Antiviral macrocyclic compounds |
| 01/20/2000 | WO2000002860A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | WO2000002858A1 Aminoiminoquinone and aminoquinine alkaloid compounds as capase inhibitors |
| 01/20/2000 | WO2000002839A1 Cytokine production and tyrosine kinase inhibitors |
| 01/20/2000 | WO2000002590A1 Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
| 01/20/2000 | WO2000002587A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/20/2000 | WO2000002584A2 Cancer treatment methods using antibodies to aminophospholipids |
| 01/20/2000 | WO2000002583A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 01/20/2000 | WO2000002581A1 Antigenic peptides derived from telomerase |
| 01/20/2000 | WO2000002571A1 Method of preparation and pharmaceutical composition of an uncaria water soluble extract |
| 01/20/2000 | WO2000002555A1 Methods and compositions for the treatment of chronic lymphocytic leukemia |
| 01/20/2000 | WO2000002544A2 Use of piperine for treating skin pigmentation disorders |
| 01/20/2000 | WO1999059633A8 Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| 01/20/2000 | WO1999059526A3 Protease inhibitors |
| 01/20/2000 | WO1999058544A9 Hybrid anthracyclines from genetically engineered streptomyces galilaeus strains |
| 01/20/2000 | WO1999056773A3 Composition comprising tumor cells and extracts and method of using thereof |
| 01/20/2000 | WO1999051742A3 Dadd, death activator death domain protein |
| 01/20/2000 | WO1999049037A3 Protein phosphatase-related molecules |
| 01/20/2000 | WO1999048916A3 Hypoxia-inducible human genes, proteins, and uses thereof |
| 01/20/2000 | WO1999047674A3 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/20/2000 | WO1999038964A3 Promoter regions of the mouse and human telomerase rna component genes |
| 01/20/2000 | DE19831710A1 New diacyl-hydrazine derivatives, are integrin inhibitors useful for treating e.g. thrombosis, cardiac infarction, tumors, osteoporosis, inflammation or infection |
| 01/20/2000 | CA2748996A1 Antigenic peptides derived from telomerase |
| 01/20/2000 | CA2337438A1 Novel inhibitors of angiogenesis and tumor growth |
| 01/20/2000 | CA2337258A1 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | CA2336932A1 Methods and compositions for the treatment of chronic lymphocytic leukemia |
| 01/20/2000 | CA2336848A1 Novel angiogenesis inhibitors |
| 01/20/2000 | CA2335382A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 01/20/2000 | CA2335090A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 01/20/2000 | CA2333928A1 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | CA2333893A1 Delta cleavage products and methods based thereon |
| 01/20/2000 | CA2332641A1 Dolastatin 15 derivatives |
| 01/20/2000 | CA2332311A1 Disintegrin homologs |
| 01/20/2000 | CA2332307A1 Human transport protein homologs |
| 01/20/2000 | CA2331789A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/19/2000 | EP0972837A2 Ubiquitin specific protease like protein |
| 01/19/2000 | EP0972831A1 Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer |
| 01/19/2000 | EP0972782A1 Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it |
| 01/19/2000 | EP0972780A1 Il-6 antagonist peptides |
| 01/19/2000 | EP0972762A2 Novel structural analogues of vitamin D |
| 01/19/2000 | EP0972528A2 Radioimmunoconjugate for use in human therapy and its preparation |
| 01/19/2000 | EP0972517A2 Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours |
| 01/19/2000 | EP0972515A2 Cyclooxygenase Inhibitor |
| 01/19/2000 | EP0972200A1 Screening and treatment using complement regulator or receptor proteins |
| 01/19/2000 | EP0972063A2 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| 01/19/2000 | EP0972052A1 Keratinocyte derived kallikrein |
| 01/19/2000 | EP0972047A2 Papilloma virus main capsid protein and the use thereof in diagnosis, therapy and vaccination |
| 01/19/2000 | EP0972041A1 Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| 01/19/2000 | EP0972040A1 Human gtp binding protein |
| 01/19/2000 | EP0972038A1 Human tumorigenesis associated protein, htap |
| 01/19/2000 | EP0972037A2 $g(b)-CATENIN, TCF-4, AND APC INTERACT TO PREVENT CANCER |
| 01/19/2000 | EP0972035A1 Human tumor suppressor |
| 01/19/2000 | EP0972034A1 Bi- or multifunctional molecules based on a dendroaspin scaffold |
| 01/19/2000 | EP0972033A1 Modulators of the function of receptors of the tnf/ngf receptor family |
| 01/19/2000 | EP0972026A2 Secreted proteins and polynucleotides encoding them |
| 01/19/2000 | EP0972024A1 A tumor suppressor designated ts10q23.3 |
| 01/19/2000 | EP0972022A2 Polynucleotides and polypeptides encoding receptors |
| 01/19/2000 | EP0972019A1 Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer |
| 01/19/2000 | EP0971959A1 Humanized antibodies and methods for forming humanized antibodies |
| 01/19/2000 | EP0971955A1 Secreted proteins |
| 01/19/2000 | EP0971953A1 Vp22 proteins and uses thereof |
| 01/19/2000 | EP0971952A2 Diagnosis method and reagents |
| 01/19/2000 | EP0971950A2 Secreted proteins and polynucleotides encoding them |
| 01/19/2000 | EP0971948A2 Inhibitors for urokinase receptor |
| 01/19/2000 | EP0971925A1 Pyrimidopyrimidine compounds |
| 01/19/2000 | EP0971921A1 2-aryl-naphthyridin-4-ones as antitumor agents |
| 01/19/2000 | EP0971888A1 2-alkyl-19-nor-vitamin d compounds |
| 01/19/2000 | EP0971887A1 Metalloproteinase inhibitors |
| 01/19/2000 | EP0971883A1 Retinoid-like compounds |
| 01/19/2000 | EP0971748A2 Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy |
| 01/19/2000 | EP0971745A2 Gel delivery vehicles for anticellular proliferative agents |
| 01/19/2000 | EP0971731A1 Suppression of malignancy utilizing ribonucleotide reductase r1 |
| 01/19/2000 | EP0971723A1 Compositions and methods for inhibiting cellular proliferation |
| 01/19/2000 | EP0971717A1 Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles |
| 01/19/2000 | EP0971716A1 Bis-anthracyclines with high activity against doxorubicin resistant tumors |
| 01/19/2000 | EP0971710A1 Use of chelerythrine and radiation for tumor therapy |
| 01/19/2000 | EP0971702A1 Microgranules containing cisplatin |
| 01/19/2000 | EP0971701A1 Method for removing high boiling solvents from drug formulations by vacuum drying |
| 01/19/2000 | EP0971692A2 Specific magnetosome, method for the production and use thereof |
| 01/19/2000 | EP0971601A1 Decaffeinated mate extracts and the use thereof |
| 01/19/2000 | EP0971585A1 Method of inhibiting cancer growth |
| 01/19/2000 | EP0772631A4 Processes for the purification of human recombinant decorin and the detection of guanidinium ions |
| 01/19/2000 | EP0728144B1 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases |
| 01/19/2000 | EP0726899B1 Novel pyrazine carboxamide derivatives, their production and their use in medicaments |
| 01/19/2000 | EP0701440B1 Tri(platinum) complexes |
| 01/19/2000 | CN1242045A Immunotherapy and improved vaccines |
| 01/19/2000 | CN1241999A Vitamin D3 derivatives |